Polyrizon Prepares Clinical Strategy for Allergy Blocker PL-14

Polyrizon Ltd. ( (PLRZ) ) has shared an announcement.

On March 27, 2025, Polyrizon Ltd. announced the structuring of its clinical strategy for its intranasal allergy blocker, PL-14, in preparation for a pre-submission meeting with the FDA. The company plans to conduct comprehensive clinical studies to evaluate the efficacy, safety, and user experience of PL-14, aiming to advance towards regulatory approval and commercialization. These studies are expected to begin in late 2025 to early 2026 in the U.S. and Europe, potentially impacting the company’s market positioning by addressing the needs of millions suffering from allergic rhinitis.

More about Polyrizon Ltd.

Polyrizon Ltd. is a biotech company specializing in the development of innovative medical device hydrogels delivered as nasal sprays. These sprays form a thin hydrogel-based shield in the nasal cavity, providing a barrier against viruses and allergens. Their proprietary Capture and Contain (C&C) technology acts as a ‘biological mask’ and is being further developed for drug delivery through nasal sprays.

YTD Price Performance: -74.32%

Average Trading Volume: 599,383

Technical Sentiment Signal: Strong Buy

Find detailed analytics on PLRZ stock on TipRanks’ Stock Analysis page.